Harvard Bioscience, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-56.7M | $-12.4M | $-3.4M | $-9.5M | $-288.0K | $-7.8M | $-4.7M | $-2.9M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $1.7M | $1.7M | $1.5M | $1.5M | $1.8M | $1.9M | $2.0M | $2.4M |
| Amortization | $4.0M | $5.3M | $5.5M | $6.1M | $5.8M | $5.7M | $5.7M | $5.4M |
| Stock-Based Compensation | $1.9M | $4.3M | $5.0M | $4.4M | $4.2M | $3.6M | $3.0M | $3.0M |
| Net Cash from Operating Activities | $6.7M | $1.4M | $14.0M | $1.2M | $1.3M | $9.3M | $8.0M | $2.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.3M | $2.6M | $1.8M | $1.6M | $1.2M | $1.2M | $1.2M | $986.0K |
| Business Acquisitions | — | — | — | — | — | — | — | $68.5M |
| Net Cash from Investing Activities | $-1.9M | $-1.3M | $-1.8M | $-1.6M | $-1.3M | $-1.4M | $-229.0K | $-53.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-1.3M | $-131.0K | $-12.1M | $-2.8M | $-252.0K | $-8.0M | $-7.6M | $53.1M |
| Net Change in Cash | $4.5M | $-175.0K | $-225.0K | $-3.3M | $-496.0K | $-18.0K | $162.0K | $2.4M |
| Free Cash Flow | $5.5M | $-1.2M | $12.2M | $-438.0K | $67.0K | $8.2M | $6.8M | $1.9M |